“An exploratory randomized, double-blind, placebo- controlled trial protocol on combined Cognitive Behavioral Therapy and adjunct Brahmi (Bacopa monnieri) tablets in Premenstrual Syndrome management”

Premenstrual syndrome (PMS) is a widespread and under-recognized disorder, characterized by cyclical recurrence of physical, psychological, and behavioral symptoms during the luteal phase, significantly impacting the daily functioning of women. Cognitive Behavioral Therapy (CBT) is an established non-pharmacological strategy for PMS, while <i>Brahmi</i> (Bacopa monnieri), a classical Ayurvedic herb, has traditionally been used to enhance cognition, reduce anxiety, and support emotional balance. This exploratory study evaluates whether combining <i>Brahmi</i> with CBT offers additional benefit compared to CBT alone. It is a double-blind, randomized, placebo-controlled exploratory clinical trial (CTRI/2025/02/081239) conducted at the Amrita School of Ayurveda, Kollam, Kerala, with sponsorship from the Central Council for Research in Ayurveda Sciences (CCRAS). Forty-six women aged 18-24 years, diagnosed with moderate to severe PMS using the Premenstrual Symptoms Screening Tool (PSST) and the Daily Record of Severity of Problems (DRSP), will be recruited and randomly assigned to receive either CBT with <i>Brahmi</i> tablets or CBT with placebo tablets. The primary outcomes include reduction in PMS severity, assessed by DRSP, and improvement in quality of life measured with the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q SF). Secondary outcome is reduction in functional disability measured using the Sheehan Disability Scale. Assessments will be conducted at baseline, during treatment, and at follow-up. Statistical analysis will be carried out using repeated measures ANOVA with Bonferroni-adjusted post hoc tests, significance set at <i>p</i> < 0.05, and effect sizes reported. A limitation of this design is that it cannot disentangle the individual effects of <i>Brahmi</i> from CBT, allowing conclusions only on the combined intervention. The study aims to generate preliminary exploratory evidence for a safe, integrative, and accessible approach to PMS management in young women.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2025-09-16
DOI
https://doi.org/10.3389/fmed.2025.1657004
Citations
1
Primary Topic
Medicinal Plants and Neuroprotection
Type
article
Field-Weighted Citation Impact
2.38

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

“An exploratory randomized, double-blind, placebo- controlled trial protocol on combined Cognitive Behavioral Therapy and adjunct Brahmi (Bacopa monnieri) tablets in Premenstrual Syndrome management”

Shahid A. Khan, U. Parvathy, Hemavathi Shivapura Krishnarajabhatt, Cinu Mithra Nisa Sushilal
1 citations
Frontiers in Medicine
Medicinal Plants and Neuroprotection
2.38
article

“An exploratory randomized, double-blind, placebo- controlled trial protocol on combined Cognitive Behavioral Therapy and adjunct Brahmi (Bacopa monnieri) tablets in Premenstrual Syndrome management”

Shahid A. Khan, U. Parvathy, Hemavathi Shivapura Krishnarajabhatt, Cinu Mithra Nisa Sushilal
article en
1 citations

Abstract

Premenstrual syndrome (PMS) is a widespread and under-recognized disorder, characterized by cyclical recurrence of physical, psychological, and behavioral symptoms during the luteal phase, significantly impacting the daily functioning of women. Cognitive Behavioral Therapy (CBT) is an established non-pharmacological strategy for PMS, while <i>Brahmi</i> (Bacopa monnieri), a classical Ayurvedic herb, has traditionally been used to enhance cognition, reduce anxiety, and support emotional balance. This exploratory study evaluates whether combining <i>Brahmi</i> with CBT offers additional benefit compared to CBT alone. It is a double-blind, randomized, placebo-controlled exploratory clinical trial (CTRI/2025/02/081239) conducted at the Amrita School of Ayurveda, Kollam, Kerala, with sponsorship from the Central Council for Research in Ayurveda Sciences (CCRAS). Forty-six women aged 18-24 years, diagnosed with moderate to severe PMS using the Premenstrual Symptoms Screening Tool (PSST) and the Daily Record of Severity of Problems (DRSP), will be recruited and randomly assigned to receive either CBT with <i>Brahmi</i> tablets or CBT with placebo tablets. The primary outcomes include reduction in PMS severity, assessed by DRSP, and improvement in quality of life measured with the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q SF). Secondary outcome is reduction in functional disability measured using the Sheehan Disability Scale. Assessments will be conducted at baseline, during treatment, and at follow-up. Statistical analysis will be carried out using repeated measures ANOVA with Bonferroni-adjusted post hoc tests, significance set at <i>p</i> < 0.05, and effect sizes reported. A limitation of this design is that it cannot disentangle the individual effects of <i>Brahmi</i> from CBT, allowing conclusions only on the combined intervention. The study aims to generate preliminary exploratory evidence for a safe, integrative, and accessible approach to PMS management in young women.

Frontiers in MedicineVol. 12
Amrita Vishwa Vidyapeetham (IN)
Amrita Vishwa Vidyapeetham University
Openalex Percentile: Top 10%
Medicinal Plants and Neuroprotection
2.38
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.